Bristol-Myers Squibb and PureTech Health both backed a round that followed the $50m that PureTech spinoff Vedanta secured in 2016.

Celgene, Taikang and WuXi AppTec have all taken part in a series B round for Antengene, which is working on treatments for cancers with a focus on Southeast and East Asia.

The tissue-modelling technology developer has expanded its Osram-backed series C round to $10.3m with cash from Occident Ventures, Falk Strascheg Holding and BayBG.

Having achieved an initial close of $8m in September, the Helmholtz spinout has now closed its series C round at $10.3m.

The immuno-oncology drug developer has filed for an $86.5m offering, having raised more than $115m in equity funding from investors including Taiho and Eli Lilly.

Alphabet subsidiary GV has bolstered its biotech focus by bringing in Rosana Kapeller as an entrepreneur-in-residence and David Reshef as venture partner.

Existing investors including Institut Mérieux have added $30m to the $55.5m in series C funding secured by the gene-editing technology developer in March.

Rakuten and SBI contributed to the cancer therapy developer's series C round, which was closed with a $134m second tranche.

Tetra Discovery Partners received the equity funding from Shionogi through a development and commercialisation partnership that could top $160m.

Merck Ventures director Andreas Jurgeit has departed after two years to become a partner at another corporate investor, Lundbeckfonden Emerge.